This was a randomized, single-center trial. On the basis of standard-of-care, patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit. Patients in the control group received standard-of-care (consisting of oxygen therapy) alone. This study intends to apply Hydrogen/Oxygen Generator in clinical patients with aneurysmal subarachnoid hemorrhage (aSAH), exploring the role of hydrogen-oxygen mixed gas inhalation therapy in early brain injury, and the prevention of cerebral vasospasm and delayed cerebral ischemia, finally providing a scientific basis for hydrogen treatment of aSAH.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
206
Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
In- hospital Cerebral Vasospasm
The proportion of patients with cerebral vasospasm at day 14
Time frame: From baseline to 14 days
In- hospital Delayed Cerebral Ischemia
The proportion of patients with delayed cerebral ischemia at day 14
Time frame: From baseline to 14 days
modified Rankin Scale score
modified Rankin Scale score at 90 days after discharge
Time frame: 90 days after discharge
Montreal Cognitive Assessment score
Montreal Cognitive Assessment score at 90 days after discharge
Time frame: 90 days after discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.